Adicet Bio
ACET
54 hedge funds and large institutions have $26.8M invested in Adicet Bio in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 18 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
33% more call options, than puts
Call options by funds: $28K | Put options by funds: $21K
0.03% less ownership
Funds ownership: 0.47% → 0.44% (-0.03%)
4% less funds holding
Funds holding: 56 → 54 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
84% less capital invested
Capital invested by funds: $169M → $26.8M (-$142M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$15.9M |
| 2 |
Morgan Stanley
New York
|
+$6.5M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$3.32M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.75M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$38.2M |
| 2 |
Jennison Associates
New York
|
-$23.3M |
| 3 |
SCM
Segantii Capital Management
Hong Kong
|
-$6.65M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.42M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.54M |
ACET Hedge Fund Activity: Q4 2019 in Review
54 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2019, worth a combined $26.8M — down 84% from $169M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ACET and 16 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 20 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $15.9M. The largest seller was Invesco, exiting entirely with an estimated $38.2M sold.
- 54 institutional investors held Adicet Bio (ACET) as of Q4 2019, down from 56 in Q3 2019.
- Funds reported $26.8M of Adicet Bio stock for Q4 2019, down 84% quarter-over-quarter.
- 16 funds opened new Adicet Bio positions in Q4 2019 and 18 closed out, a net change of -2 holders.
- The largest Adicet Bio buyer in Q4 2019 was Armistice Capital, an estimated $15.9M added.
- The largest Adicet Bio seller in Q4 2019 was Invesco, an estimated $38.2M sold.
Based on aggregated 13F filings for Q4 2019.